Clinical Trials in Transplant Immunosuppression: What Have We Learned?

  • P. Schnuelle
  • F. J. van der Woude


Evidence-based medicine relies on clinical trials, which are mandatory prior to the introduction of novel therapeutic strategies into clinical practice. The experimental design most appropriate for the comparison of therapeutic intervention is the randomized controlled clinical trial. These trials are designed to assess the efficacy of treatment in quantitative terms which are frequency of defined events (primary end-points) and time course of disease. Randomization minimizes selection bias and prevents bias in the comparison between study groups due to regression toward the mean. However, there is no guarantee that bias is entirely eliminated even in a prospective study with double blinding.


Acute Rejection Graft Survival Renal Transplant Recipient Renal Allograft Mycophenolate Mofetil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Opelz G. Collaborative transplant study — 10 year report. Transplant Proc 1992; 24: 2342–2355PubMedGoogle Scholar
  2. 2.
    Hata Y, Ozawa M, Takemoto S, Cecka J. HLA matching. In: Cecka J, Terasaki P, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1996: 381–396Google Scholar
  3. 3.
    Mihastsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995, 48 (Suppl 52): S63–S69Google Scholar
  4. 4.
    Bennet W, Dem Mattos A, Meyer M, Andoh T, Barry J. Chronic cyclosporin nephropathy: The Achilles’ heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089–1100CrossRefGoogle Scholar
  5. 5.
    Opelz G. Relation between maintenance dose of cyclosporine and long-term kidney-graft survival: collaborative transplant study. Transplant Proc 1998; 30: 1716–1717PubMedCrossRefGoogle Scholar
  6. 6.
    Hutchinson IV, Pravica V, Perrey C, Sinnott P. Cytokine gene polymorphisms and relevance to forms of rejection. Transplant Proc 1999; 31: 734–736PubMedCrossRefGoogle Scholar
  7. 7.
    Shin G, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Sunthanthiran M. In vivo expression of transforming growth factor-beta 1 in humans: stimulation by cyclosporine. Transplantation 1998; 65: 313–318PubMedCrossRefGoogle Scholar
  8. 8.
    Dantal J, Hourmant M, Cantarovitch D, Giral M, Blancho G, Dreno B, Soulillou JP. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623–628PubMedCrossRefGoogle Scholar
  9. 9.
    Keown P. Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Neoral Study Group. Kidney Int 1998; 54: 938–944PubMedCrossRefGoogle Scholar
  10. 10.
    Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffrey J, Russell D, Stiller C, Muirhead N, Cole E, Paul L, Zaltzman J, Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen J, Belitsky P, Parfrey P. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744–1752PubMedCrossRefGoogle Scholar
  11. 11.
    Cole E, Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffrey J, Russell D, Stiller C, Muirhead N, Paul L, Zaltzman J, Loertscher R, Daloze P, Dandavino R, Boucher A, Handa P, Lawen J, Belitsky P, Parfrey P, Tan A, Hendricks L. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1998; 65: 505–510PubMedCrossRefGoogle Scholar
  12. 12.
    Hall BM, Tiller DJ, Hardie I, Mahony J, Mathew T, Thatcher G, Miach P, Thomson N, Sheil AG. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499–1507PubMedCrossRefGoogle Scholar
  13. 13.
    Kootte AM, Lensen LM, van Es LA, Paul LC. Controlled cyclosporine conversion at three months after renal transplantation. Long-term results. Transplantation 1988; 46: 677–680PubMedCrossRefGoogle Scholar
  14. 14.
    Sweny P, Lui SF, Scoble JE, Varghese Z, Fernando ON, Moorhead JF. Conversion of stable renal allografts at one year from cyclosporin A to azathioprin: a randomized controlled study. Transpl Int 1990; 3: 19–22PubMedCrossRefGoogle Scholar
  15. 15.
    Isoniemi H. Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two years results in kidney transplant patients. Transpl Int 1991; 4: 31–37PubMedCrossRefGoogle Scholar
  16. 16.
    Heim-Duthoy KL, Chitwood KK, Tortorice KL, Massy ZA, Kasiske BL. Elective cyclosporine withdrawal 1 year after renal transplantation. Am J Kidney Dis 1994; 24: 846–853PubMedGoogle Scholar
  17. 17.
    Delmonico FL, Conti D, Auchincloss H Jr, Russell PS, Tolkoff-Rubin N, Fang LT, Cosimi AB. Long-term, low-dose cyclosporine treatment of renal allograft recipients. A randomized trial. Transplantation 1990; 49: 899–904PubMedCrossRefGoogle Scholar
  18. 18.
    Hiesse C, Neyrat N, Deglise-Favre A, Lantz 0, Bensadoun H, Bonigeit G, Charpentier B, Fries D. Randomized prospective trial of elective cyclosporine withdrawal from triple therapy at 6 months after cadaveric renal transplantation. Transplant Proc 1991; 23: 987–989PubMedGoogle Scholar
  19. 19.
    Spielberger M, Aigner F, Schmid T, Bösmüller C, Königsrainer A, Margreiter R. Long-term results of cadaveric renal transplantation after conversion from cyclosporine to azathioprine: a controlled randomized trial. Transplant Proc 1988; 20: 169–170PubMedGoogle Scholar
  20. 20.
    Büsing M, Hölzer H, Schareck WD, Meliert J, Greger B, Hopt UT, Lauchart W. Is long-term therapy without cyclosporin A (CsA) indispensable or dangerous? One-year results of a prospective randomized trial. Transplant Proc 1989; 21: 1601–1603PubMedGoogle Scholar
  21. 21.
    Sagalowski AI, Reisman ME, Dawidson I, Toto R, Peters PC, Helderman JH. Late cyclosporine conversion carried risk of irreversible rejection. Transplant Proc 1988; 20: 157–160Google Scholar
  22. 22.
    Land W, Castro LA, Hillebrand G, Günther K, Gokel JM. Conversion rejection consequences by changing the immunosuppressive therapy from cyclosporine to azathioprine after kidney transplantation. Transplant Proc 1983: 15:2857–2861Google Scholar
  23. 23.
    Woodle ES, Heffron TG, Stuart JK, Thistlethwaite JR Jr, Stuart FP. Effect of discontinuing or restricting cyclosporine on late renal allograft rejection and function. Transplant Proc 1989; 21: 1641–1642PubMedGoogle Scholar
  24. 24.
    Venning MC, Lennard TWJ, Stevens ME, Proud G, Ward MK, Elliott RW, Taylor RM, Wilkinson R. Cyclosporin A treatment with successful selective conversion after six months in 70 renal allograft recipients. Transplant Proc 1989; 21: 1633–1634PubMedGoogle Scholar
  25. 25.
    Veiten PS, Taylor JD, Feehally J, Walls J, Bell PRF. Elective conversion from cyclosporine to azathioprine: long-term follow-up. Transplant Proc 1987; 19: 2017Google Scholar
  26. 26.
    Oka T, Omori Y, Aikawa I, Yasumura T, Yoshimura N, Yoshida T. Early conversion from cyclosporine to combination therapy with azathioprine in living related kidney transplantation. Transplant Proc 1989; 21: 1628–1630PubMedGoogle Scholar
  27. 27.
    Maddux MS, Veremis SA, Bauma WD, Pollak R, Mozes MF. Conversion from cyclosporine to azathioprine after renal transplantation: long-term effects on renal function, rejection, and allograft survival. Transplant Proc 1988; 20: 152–154PubMedGoogle Scholar
  28. 28.
    Gonwa TA, Nghiem DD, Schulak JA, Corry RJ. Results of conversion from cyclosporine to azathioprine in cadaveric renal transplantation. Transplantation 1987; 43: 225–228PubMedCrossRefGoogle Scholar
  29. 29.
    Kaiser BA, Lawless ST, Palmer JM, Dunn SP, Polinsky MS, Baluarte HJ. Safe conversion from cyclosporine to azathioprine with improved renal function in pediatric renal transplantation. Pediatr Nephrol 1989; 3: 401–405PubMedCrossRefGoogle Scholar
  30. 30.
    Kasiske BL, Heim-Duthoy K, Ma JZ. Elective cyclosporine withdrawal after renal transplantation. JAMA 1993; 269: 395–400PubMedCrossRefGoogle Scholar
  31. 31.
    Hollander AAMJ, van Saase JLMC, Kootte AMM, van Dorp WT, van Bockel HJ, van Es LA, van der Woude FJ. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610–614PubMedCrossRefGoogle Scholar
  32. 32.
    European FK506 Multicentre Liver Study Group: Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423–428CrossRefGoogle Scholar
  33. 33.
    The U.S. Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110–1115CrossRefGoogle Scholar
  34. 34.
    Sher LS, Cosenza CA, Michel J, Makowka L, Miller CM, Schwartz ME, Busuttil R, McDiarmid S, Burdick JF, Klein AS, Esquivel C, Klintmalm G, Levy M, Roberts JP, Lake JR, Kalayoglu M, D’Alessandro AM, Gordon RD, Stieber AC, Shaw BW Jr, Thistlethwaite JR, Whittington P, Wiesner RH, Porayko M, Cosimi AB et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation 1997; 64: 258–263PubMedCrossRefGoogle Scholar
  35. 35.
    Otto MG, Mayer AD, Clavien PA, Cavallari A, Gunawardena KA, Mueller EA. Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. Transplantation 1998; 66: 1632–1640PubMedCrossRefGoogle Scholar
  36. 36.
    Jordan ML, Shapiro R, Vivas CA, Scantlebury P, Rhandhawa P, Carrieri G, McCauley J, Demetris AJ, Tzakis A, Fung JJ, Simmons RL, Hakala TR, Starzl TE. FK506 “Rescue” for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860–865PubMedCrossRefGoogle Scholar
  37. 37.
    Jordan ML, Naraghi R, Shapiro R, Smith D, Vivas CA, Scantlebury VP, Gritsch HA, McCauley J, Rhandhawa P, Demetris AJ, McMichael J, Fung JJ, Starzl TE. Tacrolimus rescue therapy for renal allograft rejection — five-year experience. Transplantation 1997; 63: 223–228PubMedCrossRefGoogle Scholar
  38. 38.
    Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, Pirsch JD, Sollinger H, Vincenti F, Burrows L, Schwartz B, Danovitch GM, Wilkinson AH, Shaffer D, Simpson MA, Freeman RB, Rohrer RJ, Mendez R, Aswad S, Munn SR, Wiesner RH, Delmonico FL, Neylan J, Whelchel J. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996; 62: 594–599PubMedCrossRefGoogle Scholar
  39. 39.
    Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436–443PubMedCrossRefGoogle Scholar
  40. 40.
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977–983PubMedCrossRefGoogle Scholar
  41. 41.
    Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736–1740PubMedCrossRefGoogle Scholar
  42. 42.
    Jensik S. Tacrolimus (FK506) in kidney transplantation: three year survival results of the U.S. multicenter, randomized, comparative trial: FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216–18PubMedCrossRefGoogle Scholar
  43. 43.
    Pichlmayr R for the European Mycophenol Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–1325Google Scholar
  44. 44.
    Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group: Mycphenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–232PubMedCrossRefGoogle Scholar
  45. 45.
    Keown PA for the Tricontinental Mycophenolat Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–1037CrossRefGoogle Scholar
  46. 46.
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients. A pooled efficacy analysis of three randomized, double-blind clinical studies in prevention of rejection. Transplantation 1997; 63: 39–47PubMedCrossRefGoogle Scholar
  47. 47.
    Mathew T. A blinded, long-term, randomized, multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years: Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450–1454PubMedCrossRefGoogle Scholar
  48. 48.
    Cho S, Hodge E, Navarro M, and the International Mycophenolate Mofetil Renal Study Groups. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. Transplant Proc 1999; 31: 322–323PubMedCrossRefGoogle Scholar
  49. 49.
    Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Costanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66:507–515PubMedCrossRefGoogle Scholar
  50. 50.
    Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball PM, Sanyal AJ, Wolfe L, Chodorov A, Posner MP. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66: 1616–1621PubMedCrossRefGoogle Scholar
  51. 51.
    Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 1395–1398PubMedCrossRefGoogle Scholar
  52. 52.
    Sollinger HW, Beizer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT et al. RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513–518PubMedCrossRefGoogle Scholar
  53. 53.
    The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of first acute renal allograft rejection. Transplantation 1998; 65: 235–241Google Scholar
  54. 54.
    Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706–1710PubMedCrossRefGoogle Scholar
  55. 55.
    Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic rejection. Transplantation 1998; 65: 661–667PubMedCrossRefGoogle Scholar
  56. 56.
    Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosorine combination regimen for renal transplantation. Transplantation 1998; 66: 1040–1046PubMedCrossRefGoogle Scholar
  57. 57.
    Groth CG, Bäckman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattström C, Charpentier B for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036–1042PubMedCrossRefGoogle Scholar
  58. 58.
    Kahan BD. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients. Transplant Proc 1998; 30: 2185–2188PubMedCrossRefGoogle Scholar
  59. 59.
    Halloran PF, Aprile MA, Farewell V, Ludwin D, Smith EK, Tsai SY, Bear RA, Cole EH, Fenton SS, Cattran DC. Early function as the principal correlate of graft survival. Transplantation 1988; 46: 223–228PubMedCrossRefGoogle Scholar
  60. 60.
    Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968–974PubMedCrossRefGoogle Scholar
  61. 61.
    Tejani AH, Sullivan EK, Alexander SR, Fine RN, Harmon WE, Kohaut EC. Predictive factors for delayed graft function (DGF) and its impact on renal graft survival in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999; 3: 293–300PubMedCrossRefGoogle Scholar
  62. 62.
    Lehtonen SR, Isoniemi HM, Salmela KT, Taskinen EI, von Willebrand EO, Ahonen JP. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 1997; 64: 103–107PubMedCrossRefGoogle Scholar
  63. 63.
    Mareen R, Orofino L, Pascual J, de la Cal MA, Teruel JL, Villafruela JJ, Rivera ME, Mampaso F, Burgos FJ, Ortuno J. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 1998; 66: 461–466CrossRefGoogle Scholar
  64. 64.
    Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337–342CrossRefGoogle Scholar
  65. 65.
    Norman DJ, Kahana L, Stuart FP Jr, Thistlethwaite JR Jr, Shield CF, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44–50PubMedCrossRefGoogle Scholar
  66. 66.
    Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DE, Najarian JS. Sequential therapy — a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allografts. Transplantation 1992; 54: 50–56PubMedCrossRefGoogle Scholar
  67. 67.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 1994; 57: 377–384PubMedCrossRefGoogle Scholar
  68. 68.
    Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Transplantation 1995; 59: 830–840PubMedGoogle Scholar
  69. 69.
    Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG. A randomized, double-blinded comparison of thymoglobin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011–1018PubMedCrossRefGoogle Scholar
  70. 70.
    Kasiske BL, Johnson HJ, Goerdt PJ, Heim-Duthoy KL, Rao VK, Dahl DC, Ney AL, Andersen RC, Jacobs DM, Odland MD. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. Am J Kidney Dis 1997; 30: 539–645CrossRefGoogle Scholar
  71. 71.
    Shield CF, Edwards EB, Davies DB, Daily OP. Antilymphocyte induction therapy in cadaver renal transplantation. A retrospective, multicenter United Network for Organ Sharing study. Transplantation 1997; 63: 1257–1263PubMedCrossRefGoogle Scholar
  72. 72.
    Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of antilymphocyte induction therapy on renal allograft survival: A meta-analysis. J Am Soc Nephrol 1997; 8: 1771–1777PubMedGoogle Scholar
  73. 73.
    Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 1995; 60: 1220–1224PubMedGoogle Scholar
  74. 74.
    Abramowicz D, Norman DJ, Goldman M, De Pauw L, Kinnaert P, Kahana L, Thistlethwaite JR, Shield CF, Monaco AP, Vanherweghem JL, et al. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant Proc 1995; 27: 852–853PubMedGoogle Scholar
  75. 75.
    Swinnen U, Costanzo-Nordin MR, Fisher SG, O’Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723–1728PubMedCrossRefGoogle Scholar
  76. 76.
    Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–1516PubMedCrossRefGoogle Scholar
  77. 77.
    Hourmant M, Bedrossian J, Durand D, Lebranchu Y, Renoult E, Caudrelier P, Buffet R, Soulillou JP. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996; 62: 1565–1570PubMedCrossRefGoogle Scholar
  78. 78.
    Salmela K, Wrammer R, Ekberg H, Hauser I, Bentdal 0, Lins LE, Isoniemi H, Backman L, Persson N, Neumayer HH, Jorgensen PF, Spieker C, Hendry B, Nicholls A, Kirste G, Hasche G. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Study Group. Transplantation 1999; 67: 729–736PubMedCrossRefGoogle Scholar
  79. 79.
    Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Robillard N, Hourmant M, Hirn M, Jacques Y. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175–1182PubMedCrossRefGoogle Scholar
  80. 80.
    Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107–113PubMedCrossRefGoogle Scholar
  81. 81.
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP for the CHIB 201 International Study Group. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193–1198PubMedCrossRefGoogle Scholar
  82. 82.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J for the Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–165PubMedCrossRefGoogle Scholar
  83. 83.
    Kahan BD, Rajagopalan PR, Hall M for the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276–284PubMedCrossRefGoogle Scholar
  84. 84.
    Mulloy LL, Wright F, Hall ML, Moore M. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant Proc 1999; 31: 1210–1213PubMedCrossRefGoogle Scholar
  85. 85.
    Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829–839PubMedCrossRefGoogle Scholar
  86. 86.
    Kasiske B, Guijarro C, Massy Z, Wiederkehr M, Ma J. Cardiovascular diseases after renal transplantation. J Am Soc Nephrol 1996; 7: 971–977PubMedGoogle Scholar
  87. 87.
    Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443–446 88.PubMedCrossRefGoogle Scholar
  88. Maiorca R, Cristinelli L, Brunori G et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc 1988; 20: 121–125PubMedGoogle Scholar
  89. 89.
    Schulak JA, Mayers JT, Moritz CE, Hricik DE. A prospective randomized trial of prednisolone versus no prednisolone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients. Transplantation 1990; 49: 327–332PubMedCrossRefGoogle Scholar
  90. 90.
    Gulanikar AC, Belitsky P, MacDonald AS, Cohen A, Bitter-Suermann H. Randomized controlled trial of steroids versus no steroids in stable cyclosporine treated renal graft recipients. Transplant Proc 1991; 23: 990–991PubMedGoogle Scholar
  91. 91.
    Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643–648PubMedCrossRefGoogle Scholar
  92. 92.
    Hollander HA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294–301PubMedGoogle Scholar
  93. 93.
    Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid-free immunosuppression in cyclosporine-treated transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300–1305PubMedGoogle Scholar
  94. 94.
    Sinclair NRS, for the Canadian Multicentre Transplant Study Group. Low-dose steroid therapy in cyclosporine treated renal transplant recipients with well functioning grafts. Can Med Assoc J 1992; 147: 645–657Google Scholar
  95. 95.
    Lebranchu Y for the M 55002 Study Group. Comparison of two corticosteroid regimens in combination with cellcept and cyclosporine A for prevention of acute allograft rejection: 12 month results of a double-blind, randomized multi-center study. Transplant Proc 1999; 31: 249–250PubMedCrossRefGoogle Scholar
  96. 96.
    Ahsan N, Hricik D, Matas A, Rose S, Tomlanovich S, Wilkinson A, Ewell M, Mcintosh M, Stablein D, Hodge E. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil—a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865–1874PubMedCrossRefGoogle Scholar
  97. 97.
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64: 1755–1760PubMedCrossRefGoogle Scholar
  98. 98.
    Jordan ML, Chakrabarti P, Luke P, Shapiro R, Vivas CA, Scantlebury VP, Fung JJ, Starzl TE, Corry RJ. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation 2000; 69: 265–271PubMedCrossRefGoogle Scholar
  99. 99.
    Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083–1091PubMedCrossRefGoogle Scholar
  100. 100.
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, Mcintosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1966. N Engl J Med 2000; 342: 605–612PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • P. Schnuelle
  • F. J. van der Woude

There are no affiliations available

Personalised recommendations